Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world.
By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases.
WHAT WE DO
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 1⁄2 hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors.
GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs.
Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.
GWHP has partnered with several companies in the health care industry and enjoy the power, resources and availability to vertically integrate.
GWHP can identify a new virus and create a specific test within 8 -12 weeks and for a fraction of the cost of its competitors.
Global WholeHealth Partners is the only company with the Rapid Diagnostic Kits to test for Ebola and ZIKA.
The Rapid Diagnostic Kits do not have to be refrigerated and last up to 18 months.